Reverse DCF
What growth does the market imply for NEPHROPLUS?
Working backwards from the current price to find the FCF growth assumption baked in.
unrealistic
35.4% implied annual FCF growth
The market is pricing in hyper-growth that virtually no established company has sustained for 10 years. This implies either a structural disruption scenario or significant overvaluation.
Current Price
₹534
Historical Growth
20.0%
FCF Yield
0.65%
Price / FCF
155.0x
Plain English
To justify today's price of $533.55, NEPHROPLUS.NS needs to grow its free cash flow at 35.4% per year for the next 10 years. That is 15.4% faster than its historical growth rate of 20.0%. At its historical growth rate, the stock cannot justify its current price within a 20-year horizon. The market is pricing in a step-change in performance.
Adjust Assumptions
Growth Scenarios
What the stock is worth at different growth assumptions
| Scenario | FCF Growth | Implied IV | MoS vs Price |
|---|---|---|---|
| GDP rate | 10.0% | ₹67 | -87.5% |
| Half implied | 17.7% | ₹132 | -75.4% |
| Historical | 20.0% | ₹159 | -70.1% |
| Implied | 35.4% | ₹531 | -0.5% |
See full DCF analysis
Bear/base/bull scenarios, sensitivity heatmap, Monte Carlo, and more.
Run Full Analysis →This is an analytical tool, not investment advice. Implied growth is a mathematical inversion of the DCF model and depends on WACC and terminal growth assumptions. YieldIQ is not registered with SEBI as an investment adviser.